VYNE Therapeutics Amends Merger Agreement with Yarrow Bioscience, Introduces Pre-Funded Warrants

summarizeSummary

VYNE Therapeutics Inc. amended its merger agreement with Yarrow Bioscience, Inc., introducing pre-funded warrants to manage beneficial ownership limitations for Yarrow shareholders and clarifying pre-closing dividend distribution.

check_boxKey Events

• Merger Agreement Amendment

  VYNE Therapeutics Inc. entered into an amendment to its Agreement and Plan of Merger and Reorganization with Yarrow Bioscience, Inc., originally dated December 17, 2025.

• Introduction of Pre-Funded Warrants

  The amendment provides for the issuance of pre-funded warrants to Yarrow capital stock holders if their post-merger VYNE Common Stock holdings would exceed a beneficial ownership limitation (default 9.99%). These warrants allow them to purchase VYNE Common Stock for a nominal exercise price of $0.0001.

• Clarification of Parent Pre-Closing Dividend

  The amendment clarifies that the Parent Pre-Closing Dividend may be awarded to holders of both outstanding VYNE Common Stock and shares underlying certain existing Parent Warrants, in accordance with their terms.

auto_awesomeAnalysis

VYNE Therapeutics Inc. has amended its merger agreement with Yarrow Bioscience, Inc. to introduce pre-funded warrants. These warrants will be issued to Yarrow shareholders whose post-merger VYNE stock ownership would exceed a beneficial ownership limitation, allowing them to acquire shares later for a nominal exercise price. This mechanism is designed to facilitate the merger by managing ownership thresholds for certain investors. The amendment also clarifies the distribution terms for the Parent Pre-Closing Dividend, ensuring it applies to both outstanding common stock and shares underlying existing Parent Warrants. While the pre-funded warrants introduce a future dilutive instrument, their primary purpose is to enable the completion of the merger by addressing beneficial ownership concerns, which is a critical step for the transaction.